Vanguard Group Inc. Grows Stock Holdings in Kura Oncology, Inc. $KURA

Key Points

• Vanguard Group Inc. increased its stake in Kura Oncology by 2.7%, acquiring an additional 129,337 shares, bringing its total ownership to 4,948,235 shares valued at approximately $32.7 million.
• Analyst ratings for Kura Oncology are mixed, with one analyst assigning a Strong Buy rating, while others have lowered their price targets, suggesting a current consensus price target of $24.10.
• Kura Oncology reported a net loss of ($0.75) earnings per share for the last quarter, significantly missing the consensus estimate of $0.15, while also reporting revenue of $15.29 million, below expectations.

Vanguard Group Inc. increased its position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 2.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,948,235 shares of the company's stock after purchasing an additional 129,337 shares during the period. Vanguard Group Inc. owned 5.72% of Kura Oncology worth $32,658,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology during the 1st quarter valued at $66,000. Flower City Capital bought a new stake in shares of Kura Oncology during the 1st quarter valued at $79,000. Corton Capital Inc. bought a new stake in shares of Kura Oncology during the 4th quarter valued at $99,000. Exchange Traded Concepts LLC raised its position in shares of Kura Oncology by 117.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,474 shares of the company's stock valued at $115,000 after purchasing an additional 9,450 shares during the period. Finally, Ameriprise Financial Inc. bought a new stake in shares of Kura Oncology during the 4th quarter valued at $130,000.

Analyst Ratings Changes

A number of analysts have issued reports on KURA shares. Wall Street Zen upgraded shares of Kura Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. Mizuho reduced their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, May 19th. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th. Finally, JMP Securities reduced their price target on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $24.10.

Kura Oncology Trading Up 0.6%

Shares of KURA stock traded up $0.05 during trading hours on Tuesday, reaching $7.95. 1,863,833 shares of the stock were exchanged, compared to its average volume of 1,898,629. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $21.57. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The company's 50-day moving average price is $6.51 and its 200-day moving average price is $6.57. The firm has a market capitalization of $690.06 million, a price-to-earnings ratio of -3.52 and a beta of 0.19.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to analysts' expectations of $64.95 million. As a group, equities analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.